Brought to you by 
Takeda co-promotes Kos's Niaspan, Advicor in US
15 Jul 2004
Executive Summary
For a period of three years, Takeda Pharmaceuticals will co-promote Kos Pharmaceuticals' drugs for cholesterol disorders, Niaspan (extended-release niacin) and Advicor (extended-release niacin and lovastatin) in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda co-promotes Kos's Niaspan, Advicor in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice